Literature DB >> 10509170

Epidemiology and natural history of schizophrenia.

E J Bromet1, S Fennig.   

Abstract

The present review explores the descriptive epidemiology of schizophrenia. Risk factors and correlates are divided into three groups based on whether the available evidence is consistent and strong, consistent and potentially strong, or inconsistent. The paper then considers epidemiologic studies of the course of illness, including a description of findings from the Suffolk County Mental Health Project. Given renewed attention to the need for preventive interventions for individuals at high risk for developing a psychotic illness, epidemiologic values have become more and more central to the conduct of clinical research.

Entities:  

Mesh:

Year:  1999        PMID: 10509170     DOI: 10.1016/s0006-3223(99)00153-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  37 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 4.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

5.  Increase in schizophrenia incidence rates: findings in a Canadian cohort born 1975-1985.

Authors:  Isabelle Bray; Paul Waraich; Wayne Jones; Serena Slater; Elliot M Goldner; Julian Somers
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-06-02       Impact factor: 4.328

6.  Cross-national comparisons: problems in interpretation when studies are based on prevalent cases.

Authors:  Evelyn J Bromet
Journal:  Schizophr Bull       Date:  2008-01-22       Impact factor: 9.306

7.  Managing schizophrenia in primary care: the utility of remission criteria as outcome indicators.

Authors:  Christopher Fear; David Yeomans; Bryan Moore; Mark Taylor; Keith Ford; Alan Currie; Joanne Hynes; Gary Sullivan; Richard Whale; Tom Burns
Journal:  Ment Health Fam Med       Date:  2009-06

8.  Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence.

Authors:  W H Man; A Pérez-Pitarch; I Wilting; E R Heerdink; W W van Solinge; A C G Egberts; A D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

9.  Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity.

Authors:  Roman Kotov; Lin T Guey; Evelyn J Bromet; Joseph E Schwartz
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

10.  Is familiality associated with downward occupation drift in schizophrenia?

Authors:  Triptish Bhatia; Satabdi Chakraborty; Pramod Thomas; Amina Naik; Sati Mazumdar; Vishwajit L Nimgaonkar; Smita N Deshpande
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.